CL2020000631A1 - Uso de anticuerpos de unión a il-1b para el tratamiento de la hepatitis alcohólica. - Google Patents

Uso de anticuerpos de unión a il-1b para el tratamiento de la hepatitis alcohólica.

Info

Publication number
CL2020000631A1
CL2020000631A1 CL2020000631A CL2020000631A CL2020000631A1 CL 2020000631 A1 CL2020000631 A1 CL 2020000631A1 CL 2020000631 A CL2020000631 A CL 2020000631A CL 2020000631 A CL2020000631 A CL 2020000631A CL 2020000631 A1 CL2020000631 A1 CL 2020000631A1
Authority
CL
Chile
Prior art keywords
treatment
alcoholic hepatitis
binding antibodies
subject
hepatitis
Prior art date
Application number
CL2020000631A
Other languages
English (en)
Spanish (es)
Inventor
Shephard Mpofu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020000631A1 publication Critical patent/CL2020000631A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CL2020000631A 2017-09-13 2020-03-11 Uso de anticuerpos de unión a il-1b para el tratamiento de la hepatitis alcohólica. CL2020000631A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762557929P 2017-09-13 2017-09-13
US201862647088P 2018-03-23 2018-03-23

Publications (1)

Publication Number Publication Date
CL2020000631A1 true CL2020000631A1 (es) 2020-09-11

Family

ID=63708416

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000631A CL2020000631A1 (es) 2017-09-13 2020-03-11 Uso de anticuerpos de unión a il-1b para el tratamiento de la hepatitis alcohólica.

Country Status (14)

Country Link
US (3) US20200207848A1 (enExample)
EP (1) EP3717006A1 (enExample)
JP (1) JP2020533353A (enExample)
KR (1) KR20200052331A (enExample)
CN (1) CN111315412A (enExample)
AU (1) AU2018333106A1 (enExample)
BR (1) BR112020004903A2 (enExample)
CA (1) CA3075711A1 (enExample)
CL (1) CL2020000631A1 (enExample)
IL (1) IL273204A (enExample)
MX (1) MX2020002813A (enExample)
RU (1) RU2020113234A (enExample)
TW (1) TW201920269A (enExample)
WO (1) WO2019053591A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026145640A1 (zh) * 2025-01-03 2026-07-09 长春金赛药业有限责任公司 一种抗IL-1β抗体的药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
AU2010306681A1 (en) * 2009-10-15 2012-04-19 Abbvie Inc. IL-1 binding proteins
US10000565B2 (en) * 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease
WO2015083120A1 (en) * 2013-12-04 2015-06-11 Novartis Ag USE OF IL-1β BINDING ANTIBODIES
MX2016014731A (es) * 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
KR101695848B1 (ko) * 2015-03-03 2017-01-13 한국과학기술원 진세노사이드 f2를 포함하는 비알코올성 간 질환 또는 인슐린 저항성의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
TW201920269A (zh) 2019-06-01
WO2019053591A1 (en) 2019-03-21
JP2020533353A (ja) 2020-11-19
MX2020002813A (es) 2020-07-21
AU2018333106A1 (en) 2020-04-02
US20200207848A1 (en) 2020-07-02
CA3075711A1 (en) 2019-03-21
EP3717006A1 (en) 2020-10-07
IL273204A (en) 2020-04-30
US20230235043A1 (en) 2023-07-27
US20210309736A1 (en) 2021-10-07
RU2020113234A3 (enExample) 2022-04-28
CN111315412A (zh) 2020-06-19
RU2020113234A (ru) 2021-10-13
KR20200052331A (ko) 2020-05-14
BR112020004903A2 (pt) 2020-09-15

Similar Documents

Publication Publication Date Title
DOP2019000201A (es) Compuestos inhibidores del vih
CO2018000809A2 (es) Anticuerpos para cd40
CO2019001043A2 (es) Composición de cannabis
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
MX2020001201A (es) Anticuerpos anti-activina a y usos de los mismos.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX2019007156A (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
MX2018012076A (es) Composiciones y anticuerpos anti proteina 3 que contiene inmunoglobulina de linfocitos t y el dominio de mucina (tim-3).
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
MA67901B1 (fr) Mirikizumab pour le traitement de la colite ulcéreuse
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
AR101740A1 (es) Terapia de combinación y composiciones
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
AR105336A1 (es) Agentes, usos y métodos para el tratamiento de la sinucleinopatía
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
CO2020004801A2 (es) Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.